Feb. 10 Quick Takes: RA, Adjuvant ready Curevo to take on Shingrix with $60M A round

Curevo Vaccine’s $60 million series A round will carry the Bothell, Wash.-based company’s shingles vaccine through top-line Phase IIb data from a 678-patient, head-to-head trial against Shingrix from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). The vaccine, CRV-101, is one of at least six seeking to challenge the blockbuster GSK product, which had £1.7 billion ($2.3 billion) in revenues last year.

RA Capital Management and Adjuvant Capital led the A round, with participation from Janus Henderson Investors, EN Investment and South Korea’s GC Pharma (KSE:006280). GC founded the company with the Mogam Institute for Biomedical Research (MIBR). ...